Arlinghaus RB - Search Results

1

p120 GAP requirement in normal and malignant human hematopoiesis.

Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak M, Szczylik C, Zon G, Arlinghaus RB, Gewirtz A, Perussia B, Calabretta B. Skorski T, et al. Among authors: arlinghaus rb. J Exp Med. 1993 Dec 1;178(6):1923-33. doi: 10.1084/jem.178.6.1923. J Exp Med. 1993. PMID: 8245773 Free PMC article.

2

Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia.

Lin H, Monaco G, Sun T, Ling X, Stephens C, Xie S, Belmont J, Arlinghaus R. Lin H, et al. Oncogene. 2005 May 5;24(20):3246-56. doi: 10.1038/sj.onc.1208500. Oncogene. 2005. PMID: 15735695

3

The involvement of Bcr in leukemias with the Philadelphia chromosome.

Arlinghaus RB. Arlinghaus RB. Crit Rev Oncog. 1998;9(1):1-18. doi: 10.1615/critrevoncog.v9.i1.10. Crit Rev Oncog. 1998. PMID: 9754444 Review.

4

Requirement of lipocalin 2 for chronic myeloid leukemia.

Arlinghaus R, Leng X. Arlinghaus R, et al. Leuk Lymphoma. 2008 Apr;49(4):600-3. doi: 10.1080/10428190701859664. Leuk Lymphoma. 2008. PMID: 18398717

5

BCR-ABL tyrosine kinase is autophosphorylated or transphosphorylates P160 BCR on tyrosine predominantly within the first BCR exon.

Liu J, Campbell M, Guo JQ, Lu D, Xian YM, Andersson BS, Arlinghaus RB. Liu J, et al. Among authors: arlinghaus rb. Oncogene. 1993 Jan;8(1):101-9. Oncogene. 1993. PMID: 8423987

6

c-Abl activates janus kinase 2 in normal hematopoietic cells.

Tao W, Leng X, Chakraborty SN, Ma H, Arlinghaus RB. Tao W, et al. Among authors: arlinghaus rb. J Biol Chem. 2014 Aug 1;289(31):21463-72. doi: 10.1074/jbc.M114.554501. Epub 2014 Jun 12. J Biol Chem. 2014. PMID: 24923444 Free PMC article.

7

Tyrosine phosphorylation of P160 BCR by P210 BCR-ABL.

Lu D, Liu J, Campbell M, Guo JQ, Heisterkamp N, Groffen J, Canaani E, Arlinghaus R. Lu D, et al. Blood. 1993 Aug 15;82(4):1257-63. Blood. 1993. PMID: 8353288 Free article.

8

Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr-abl positive 32D myeloid leukemia cells.

Guo XY, Cuillerot JM, Wang T, Wu Y, Arlinghaus R, Claxton D, Bachier C, Greenberger J, Colombowala I, Deisseroth AB. Guo XY, et al. Oncogene. 1998 Aug 20;17(7):825-33. doi: 10.1038/sj.onc.1201999. Oncogene. 1998. PMID: 9779999

9

Comparison of bcr-abl protein expression and Philadelphia chromosome analyses in chronic myelogenous leukemia patients.

Guo JQ, Lian J, Glassman A, Talpaz M, Kantarjian H, Deisseroth AB, Arlinghaus RB. Guo JQ, et al. Among authors: arlinghaus rb. Am J Clin Pathol. 1996 Oct;106(4):442-8. doi: 10.1093/ajcp/106.4.442. Am J Clin Pathol. 1996. PMID: 8853030

10

Jak2 is involved in c-Myc induction by Bcr-Abl.

Xie S, Lin H, Sun T, Arlinghaus RB. Xie S, et al. Among authors: arlinghaus rb. Oncogene. 2002 Oct 17;21(47):7137-46. doi: 10.1038/sj.onc.1205942. Oncogene. 2002. PMID: 12370803

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

262 results

Search Page

Filters